Earlier detection and treatment optimization enabled by CNSide may reduce overall LM-related healthcare costs by ~40% (33%-47%) Potential savings are driven by earlier therapeutic intervention, ...
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III ...
Using single-cell sequencing, researchers found distinct immune profiles in different CNS tumors, highlighting its potential as a prognostic tool.
Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This ...
In a recent study published in the journal Nature Medicine, a group of researchers assessed if a precise blood test matches or surpasses traditional cerebrospinal fluid (CSF) tests in detecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results